Overview
The single most cited surfacePTD-DBM
Research use onlyCell-penetrating peptide that disrupts the CXXC5–Dishevelled interaction to disinhibit Wnt/β-catenin signaling; studied preclinically for hair follicle regeneration and wound repair.
Researched goals
Areas of active research — not promised effects
Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.
Similar peptides
Related by research scope · open each to compare
Status at a glance
PTD-DBM has no FDA approval, no IND on record, and is not listed as a nominated or Category 1/2 substance under the FDA 503A bulk drug substances programme. It may be purchased and handled for legitimate non-clinical research purposes only. Human administration outside of an approved clinical study is not authorised.
Buyer-confidence index
Transparent blend · bci-1.0 · never paid-placement
Sourcing sub-inputs
5 cited sub-inputs, scored 0–100, before weighting.
Trust & provenance
Identity & chemistry
Identity & registry
- Primary name
- PTD-DBM
- Origin
- Synthetic chimeric peptide composed of a HIV-TAT-derived protein transduction domain (PTD) fused to a Dishevelled-binding motif (DBM) derived from the CXXC5 interaction interface. Developed to pharmacologically probe the CXXC5–Dvl axis identified in studies of androgenetic alopecia and cutaneous wound healing.
Registry IDs
- PubChem CID
- 176453931
- CAS
- 1609454-11-6
- InChIKey
- IMXABKONEGYGRF-QAMUXZJLSA-N
Chemical & physical
- Molecular formula
- C124H225N61O28S2
- Molar mass
- 3082.6 g/mol
- Monoisotopic
- 3080.7498981 Da
- InChIKey
- IMXABKONEGYGRF-QAMUXZJLSA-N
- Appearance
- White to off-white lyophilised powder
- Solubility
- Soluble in DMSO and dilute aqueous buffers; limited aqueous solubility without c…
Structure & sequence
Sequence not available in current seed.
Storage, stability & degradation
Storage
Lyophilized: -20 °C, protected from light and moisture
Reconstituted: 2–8 °C, use within 7 days; avoid repeated freeze-thaw cycles
Shelf-life: Typically 2 years lyophilised per vendor specifications; not
Tell-tale degradation
Stability: Stability data from peer-reviewed sources not identified; standard peptide handling recommendations apply. The PTD sequence may increase aggregation risk at hig
Forms & specifications
- Vial sizes
- 5 mg
- Purity grades
- ≥98% HPLC
- Salt forms
- Free base (primary)
SDS & lab handling
Evidence & efficacy
Evidence at a glance
How much research exists, and of what maturity — never a verdict on whether it works.
Human efficacy is unproven: no completed, published human efficacy RCT establishes that this compound works in people. All maturity below is literature volume and kind — never a verdict on effect. No completed, published human efficacy RCT — capped at Preclinical.
Indexed articles by era
Volume and kind of literature, over time.
Across all eras, by kind
Mechanism research coverage
Which pathways the research probes.
Does it actually work? — proven vs anecdotal
Pharmacology
Mechanism of action
Pharmacokinetics (ADME)
PK–PD note: No formal pharmacokinetic data published for PTD-DBM. Topical application has been used in all reported preclinical studies; systemic exposure following topical dosing has not been characterised in pe…
Evidence & literature
Reading the evidence
Key reviews & evidence-gap sources
Human-trial pipeline
No registered human trials found for this compound.
- Status
- No registered trials found
Safety profile
Summary (literature)
No systemic toxicity or significant adverse effects were reported in published mouse topical application studies or in vitro dermal cell culture models at research concentrations; however, formal preclinical toxicology studies (GLP toxicology, genotoxicity, reproductive toxicity)…
WADA status
Not specifically listed on the WADA 2026 Prohibited List. PTD-DBM has no known ergogenic application and does not fall under any named category or compound clas…
Routes of administration
How PTD-DBM has been studied — pharmacology, not a protocol. RUO.Dominant research route & oral stability
Dominant research route: Topical
Topical (TOP)
Topical application to dorsal skin of C57BL/6N mice; assessed hair regrowth and wound-induced hair follicle neogenesis (WIHN); also applied to full-thickness skin wounds on mouse backs
Bioavailability: The PTD (protein transduction domain) component is intended to enable the peptide to cross the stratum corneum and enter dermal papilla cells; no human PK/bioavailability data published
Foundational 2017 Journal of Investigative Dermatology study (Lee et al., PMID 28595998) applied PTD-DBM topically to bald laboratory mice, resulting in new hair follicle growth; combination with valproic acid (VPA) further induced hair regrowth and WIHN. No completed peer-reviewed human efficacy trials as of 2026.
Topical (cosmetic serum) (TOP)
Aggregate community use of marketed cosmetic hair serums (e.g., InfiniWell PTD-DBM + Methyl Vanillate) applied to scalp; no controlled human PK study
Bioavailability: No published human bioavailability or absorption data; cosmetic formulations are not FDA-reviewed for efficacy
De-identified aggregate community reports describe topical scalp application of cosmetic PTD-DBM serums; these are cosmetic products, not approved drugs, and lack controlled human pharmacokinetic characterization.
Dosage reference & research tools
Dosage reference spectrum
CitedStudied doses (animal / preclinical)
Preclinical mouse studies employed topical application of PTD-DBM, typically as a solution applied to shaved or wounded skin; precise mg/kg or mg/cm² doses used in published protocols are not uniformly reported in accessible abstracts (PMIDs 26056233, 36854308, 36831222). No systemic dosing regimens have been published.
UGCCommunity-reported (not validated · not medical advice)
DISCLAIMER: Community and vendor sources report typical research preparation concentrations of approximately 1–5 mg reconstituted in dimethyl sulfoxide (DMSO) or aqueous carrier for topical application in animal studies. These figures are drawn from non-peer-reviewed vendor/community sources and are not validated human dosing guidance. PeptideCompass does not endorse or recommend any dosing regimen.
Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.
Reconstitution calculator
Research unit-conversion only · not for human use
Vendors & price intelligence
United StatesVendor & price comparison
Sorted A–Z by vendor — never by price
As of 2026-08-06· research-catalog listings, dated & cited — no ranking, no commission earned, never sorted by price. Research use only.
Crawled vendor listings, sorted A–Z by vendor — never by price.
Price-per-mg history
Weekly median $/mg from the live vendor crawl.
Price distribution
Researched storefront prices, bucketed
Provisional · live crawl in progressp25 $17.80 · median $20.34 · p75 $22.88 · 7 researched vendors
Legit, COA-backed band: $17.20–$22.88/mg.
Cross-region & vial-size economics
Cross-region pricing
- United States (researched)
- $20.34/mg
- Canada
- Collecting
- United Kingdom
- Collecting
- European Union
- Collecting
Only the US market has been researched so far — no FX conversion is applied.
Vial-size economics
- 1 mg vial
- 4 vendors offer it
- 2 mg vial
- 1 vendor offers it
- 5 mg vial
- 3 vendors offer it
- 10 mg vial
- 1 vendor offers it
Bigger vials generally lower $/mg but raise reconstitution-waste risk.
Cost & value analytics
Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.
Estimated cost of research (10 mg)
- Vial (best researched price)
- $172
- Bacteriostatic water (generic estimate)
- $6
- Syringes / supplies (generic estimate)
- $12
Vendor reliability
Bulk / B2B procurement
Licensed clinics & 503A
Segregated from gray-market research vendors · shown only where lawful.
Quality, verification & alerts
Quality, testing & COA verification
What each test proves — general guidance, plus this compound's researched purity data
Purity on the current market (researched)
96.12% (single supplier COA, MedChemExpress Cat. HY-P11112); research-vendor marketing claims of '99% purity' are unverified by independent lab data retrieved here.
Independent labs cited for this compound
- Expected MS
- 3082.6 Da
Counterfeit & recall alerts
No FDA recalls, enforcement actions, or criminal investigations naming PTD-DBM specifically were found in the sources retrieved. The compound is not on the FDA Category 2 'Do Not Compound' list and has no approved NDA/IND.
Buyer red-flag checklist
Manufacturing, grade & supply chain
GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.
Underdosing / mislabeling: No independent lab test results (Janoshik/MZ Biolabs/Finnrick) for PTD-DBM were retrievable; the Janoshik public results portal returned HTTP 403. No aggregate underdosing prevalence data is available for this compound.
Shipping, customs & landed cost
Regulatory & developments
United StatesRegulatory status & timeline
Latest news & developments
Every item dated & sourced
WADA anti-doping status
PTD-DBM is not approved by any governmental regulatory health authority for human therapeutic use, so it falls under WADA Prohibited List section S0 (Non-Approved Substances), which prohibits substances not approved by any governmental regulatory health authority for human therapeutic use at all times. Unregulated research peptides are cited as falling under S0.
SourcePatent & IP landscape
No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.
Use-context & responsibility
Community, sentiment & answers
FAQ
Community sentiment
Based on 40 qualifying contributions across 2 platforms, last 90 daysModerate signal
Not enough history to show a trend yet.
What this is — and is not
A read on how this compound is received in public discussion — the balance of positive, neutral and critical mentions over time.
Not a measure of whether it works, is safe, or is effective; not medical advice; the unverified opinions of anonymous community members (Layer B).
Community Sentiment — Layer B. This reflects the tone of public discussion across Reddit, Bluesky, YouTube and X over the last 90 days (as of 2025-11-12). It measures how a compound is discussed and received, not whether it is safe, effective, or appropriate for any use. It is not medical, dosing, or purchasing advice and is not an endorsement. Posts are aggregated and de-identified; individual comments, claims, and dosing discussion are never shown. Research use only.
Community themes & reported concerns
What people discuss
Reported concerns — discussion, not established effects
Reading caveats
Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.
Tools, market & meta
Research & market activity
Relative research / market volume — populated once the activity stream is wired
Ask this datasheet
Watch & listing momentum
Lifecycle & market history
Data confidence & contribute
Glossary & reading mode
Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.
Toggle plain-language ↔ scientific in the header.
Guides & explainers
Market intelligence
Citable summary (GEO)
Cell-penetrating peptide that disrupts the CXXC5–Dishevelled interaction to disinhibit Wnt/β-catenin signaling; studied preclinically for hair follicle regeneration and wound repair. Approximately 4 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research Use Only — not FDA-approved, not on 503A/503B compounding lists. Research use only.
Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.